Welcome to our dedicated page for Incyte SEC filings (Ticker: INCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Incyte Genomics Inc (INCY) SEC filings page on Stock Titan aggregates regulatory documents for Incyte Corporation, a global biopharmaceutical company focused on Oncology and Inflammation & Autoimmunity. These filings provide structured insight into how the company reports its financial condition, governance changes and material events to the U.S. Securities and Exchange Commission.
Incyte’s common stock is listed on The Nasdaq Stock Market LLC under the symbol INCY, as disclosed in Form 8‑K reports. Investors can review current reports on Form 8‑K that cover topics such as quarterly financial results, executive and board transitions, inducement equity awards and key corporate agreements. For example, recent 8‑Ks describe leadership changes in the chief executive officer and chief financial officer roles, transition and employment agreements, and announcements of quarterly earnings press releases.
Alongside 8‑Ks, users can access Incyte’s annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available in the feed) to understand segment focus, risk factors, research and development priorities, and other disclosures that frame the company’s oncology and immunology strategy. These periodic reports typically detail the status of marketed products and pipeline programs, capital structure and significant accounting policies.
For those tracking management incentives and ownership, the filings page also links to insider transaction reports on Form 4 and related beneficial ownership disclosures, where present in EDGAR. These documents show grants of stock options, restricted stock units and performance shares, such as inducement awards and executive compensation packages referenced in Incyte’s current reports.
Stock Titan enhances this information by providing AI-powered summaries that explain the key points of lengthy filings, highlight notable changes and help readers interpret complex legal and financial language. Real‑time updates from EDGAR ensure that new INCY filings—whether earnings‑related, governance‑related or tied to material clinical and commercial developments—are quickly reflected, allowing investors, researchers and other stakeholders to review the underlying documents and AI insights in one place.
Form 4 filing overview: On 07/02/2025, Incyte Corp. (INCY) Principal Accounting Officer Tray Thomas satisfied tax-withholding obligations related to previously granted restricted stock units (RSUs).
- Transaction code F denotes shares withheld by the issuer for taxes—not an open-market sale.
- Shares withheld: 897 common shares at an implied price of $68.17.
- Post-transaction holdings: 21,106 common shares, of which 13,456 are unvested RSUs.
No derivative securities were exercised or disposed of. The filing represents an administrative, non-discretionary transaction and does not signal a change in the executive’s investment thesis or company fundamentals.
FAQ
What is the current stock price of Incyte (INCY)?
What is the market cap of Incyte (INCY)?
